Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions
is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.
A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.
Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).
An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
An analysis of the partnerships that have been established in this domain, in the recent past.
A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
An analysis of the initiatives of big biopharma players engaged in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Target Disease Indication
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Lupus Nephritis
Melanoma
Multiple Myeloma
Primary Sjögren’s Syndrome
Others
Target Immune Checkpoint
B7-H3
CD38
CD40
CD47
Others
Mechanism of Action
Inhibitory
Stimulatory
Therapeutic Modality
Monoclonal Antibody
Small Molecule
Type of Therapy
Monotherapy
Combination Therapy
Route of Administration
Intravenous
Subcutaneous
Others
Key Geographical Region
North America
Europe
Asia-Pacific and the Rest of the World
Key companies covered in the report
Bristol Myers Squibb
GlaxoSmithKline
Incyte
Novartis
Trillium Therapeutics
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Other Recent Offerings
Transcripts of interviews held with the following senior level representatives of stakeholder companies
Jean-Yves Ortholand, Co-founder & Chief Executive Officer, Edelris
Björn Walse, Chief Executive Officer, SARomics Biostructures
